Strides Pharma's loss widened from Rs 4.31 crore reported in June quarter and profit for September quarter 2017 stood at Rs 8.6 crore.
Trends on SGX Nifty indicate a positive opening for the broader index in India, a gain of 55 points or 0.54 percent. Nifty futures were trading around 10,227- level on the Singaporean Exchange.
Potassium Chloride extended-release tablet is a generic version of Klor-Con extended-release tablet of Upsher-Smith and Strides is the first Indian generic company to receive this approval.
The company had posted a net profit of Rs 5.78 crore in April-June 2017, Strides Pharma said in a BSE filing.
In November 2015, Strides Arcolab had changed its name to Strides Shasun post amalgamation of Shasun Pharmaceuticals with Strides Arcolab.